FENOFIBRIC ACID capsule, delayed release

Fenofibric acid by

Drug Labeling and Warnings

Fenofibric acid by is a Prescription medication manufactured, distributed, or labeled by Macleods Pharmaceuticals Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS & USAGE

    1.1 Treatment of Severe Hypertriglyceridemia

    Fenofibric acid delayed-release capsules are indicated as adjunctive therapy to diet to reduce triglycerides (TG) in patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacological intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibric acid delayed-release capsules therapy on reducing this risk has not been adequately studied.

    1.2 Treatment of Primary Hypercholesterolemia or Mixed Dyslipidemia

    Fenofibric acid delayed-release capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia or mixed dyslipidemia.

    1.3 Limitations of Use

    Fenofibrate at a dose equivalent to 135 mg of fenofibric acid did not reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus [see Warnings and Precautions (5.1)].

    1.4 General Considerations for Treatment

    Laboratory studies should be performed to establish that lipid levels are abnormal before instituting fenofibric acid delayed-release capsules therapy.
    Every reasonable attempt should be made to control serum lipids with non-drug methods including appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that may be contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (beta-blockers, thiazides, estrogens) should be discontinued or changed if possible, and excessive alcohol intake should be addressed before triglyceride-lowering drug therapy is considered. If the decision is made to use lipid-altering drugs, the patient should be instructed that this does not reduce the importance of adhering to diet.
    Drug therapy is not indicated for patients who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL.


  • 2 DOSAGE & ADMINISTRATION

    2.1 General Considerations

    Patients should be placed on an appropriate lipid-lowering diet before receiving fenofibric acid and should continue this diet during treatment. Fenofibric acid delayed-release capsules can be taken without regard to meals. Patients should be advised to swallow fenofibric acid delayed-release capsules whole. Do not open, crush, dissolve, or chew capsules. Serum lipids should be monitored periodically.

    2.2 Severe Hypertriglyceridemia

    The initial dose of fenofibric acid delayed-release capsules are 45 to 135 mg once daily. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 135 mg once daily.

    2.3 Primary Hypercholesterolemia or Mixed Dyslipidemia

    The dose of fenofibric acid delayed-release capsule is 135 mg once daily.

    2.4 Impaired Renal Function

    Treatment with fenofibric acid delayed-release capsules should be initiated at a dose of 45 mg once daily in patients with mild to moderate renal impairment and should only be increased after evaluation of the effects on renal function and lipid levels at this dose. The use of fenofibric acid delayed-release capsules should be avoided in patients with severely impaired renal function [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

    2.5 Geriatric Patients

    Dose selection for the elderly should be made on the basis of renal function [see Use in Specific Populations (8.5)].

  • 3 DOSAGE FORMS & STRENGTHS

     45 mg capsules with reddish brown cap/yellow body size “3” capsule containing white to off white delayed release, biconvex mini tablets, with ‘C 66’ on body imprinted with black ink.
     135 mg capsules with a blue cap/yellow body size “0” capsule containing white to off white delayed release, biconvex mini tablets, with ‘C 67’ on body imprinted with black ink.


  • 4 CONTRAINDICATIONS

    Fenofibric acid is contraindicated in:
     patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)].
     patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)].
     patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)].
     nursing mothers [see Use in Specific Populations (8.2)].
     patients with hypersensitivity to fenofibric acid or fenofibrate [see Warnings and Precautions (5.9)].


  • 5 WARNINGS AND PRECAUTIONS

    5.1 Mortality and Coronary Heart Disease Morbidity

    The effect of fenofibric acid on coronary heart disease morbidity and mortality and non-cardiovascular mortality has not been established. Because of similarities between fenofibric acid and fenofibrate, clofibrate, and gemfibrozil, the findings in the following large randomized, placebo-controlled clinical studies with these fibrate drugs may also apply to fenofibric acid
    The Action to Control Cardiovascular Risk in Diabetes Lipid (ACCORD Lipid) trial was a randomized placebo-controlled study of 5518 patients with type 2 diabetes mellitus on background statin therapy treated with fenofibrate. The mean duration of follow-up was 4.7 years. Fenofibrate plus statin combination therapy showed a non-significant 8% relative risk reduction in the primary outcome of major adverse cardiovascular events (MACE), a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular disease death (hazard ratio [HR] 0.92, 95% CI 0.79-1.08) (p=0.32) as compared to statin monotherapy. In a gender subgroup analysis, the hazard ratio for MACE in men receiving combination therapy versus statin monotherapy was 0.82 (95% CI 0.69-0.99), and the hazard ratio for MACE in women receiving combination therapy versus statin monotherapy was 1.38 (95% CI 0.98-1.94) (interaction p=0.01). The clinical significance of this subgroup finding is unclear.
    The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a 5-year randomized, placebo-controlled study of 9795 patients with type 2 diabetes mellitus treated with fenofibrate. Fenofibrate demonstrated a non-significant 11% relative reduction in the primary outcome of coronary heart disease events (hazard ratio [HR] 0.89, 95% CI 0.75-1.05, p = 0.16) and a significant 11% reduction in the secondary outcome of total cardiovascular disease events (HR 0.89 [0.80-0.99], p = 0.04). There was a non-significant 11% (HR 1.11 [0.95, 1.29], p = 0.18) and 19% (HR 1.19 [0.90, 1.57], p = 0.22) increase in total and coronary heart disease mortality, respectively, with fenofibrate as compared to placebo.
    In the Coronary Drug Project, a large study of post-myocardial infarction patients treated for 5 years with clofibrate, there was no difference in mortality seen between the clofibrate group and the placebo group. There was, however, a difference in the rate of cholelithiasis and cholecystitis requiring surgery between the two groups (3.0% vs. 1.8%).
    In a study conducted by the World Health Organization (WHO), 5000 subjects without known coronary artery disease were treated with placebo or clofibrate for 5 years and followed for an additional one year. There was a statistically significant, higher age-adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p = < 0.01). Excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholecystectomy complications, and pancreatitis. This appeared to confirm the higher risk of gallbladder disease seen in clofibrate-treated patients studied in the Coronary Drug Project.
    The Helsinki Heart Study was a large (N = 4081) study of middle-aged men without a history of coronary artery disease. Subjects received either placebo or gemfibrozil for 5 years, with a 3.5 year open extension afterward. Total mortality was numerically higher in the gemfibrozil randomization group but did not achieve statistical significance (p = 0.19, 95% confidence interval for relative risk G:P = 0.91-1.64). Although cancer deaths trended higher in the gemfibrozil group (p = 0.11), cancers (excluding basal cell carcinoma) were diagnosed with equal frequency in both study groups. Due to the limited size of the study, the relative risk of death from any cause was not shown to be different than that seen in the 9 year follow-up data from WHO study (RR = 1.29). A secondary prevention component of the Helsinki Heart Study enrolled middle-aged men excluded from the primary prevention study because of known or suspected coronary heart disease. Subjects received gemfibrozil or placebo for 5 years. Although cardiac deaths trended higher in the gemfibrozil group, this was not statistically significant (hazard ratio 2.2, 95% confidence interval: 0.94-5.05).


    5.2 Hepatotoxicity

    Serious drug-induced liver injury (DILI), including liver transplantation and death, have been reported postmarketing with fenofibric acid. DILI has been reported within the first few weeks of treatment or after several months of therapy and in some cases has reversed with discontinuation of fenofibric acid treatment. Patients with DILI have experienced signs and symptoms including dark urine, abnormal stool, jaundice, malaise, abdominal pain, myalgia, weight loss, pruritus, and nausea. Many patients had concurrent elevations of total bilirubin, serum alanine transaminase (ALT), and aspartate transaminase (AST). DILI has been characterized as hepatocellular, chronic active, and cholestatic hepatitis, and cirrhosis has occurred in association with chronic active hepatitis.

    In clinical trials, fenofibric acid at a dose of 135 mg daily has been associated with increases in serum AST or ALT. The incidence of increases in transaminases observed with fenofibrate therapy may be dose related [see Adverse Reactions (6.1)].

    Fenofibric acid is contraindicated in patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Contraindications (4)]. Monitor patient’s liver function, including serum ALT, AST, and total bilirubin, at baseline and periodically for the duration of therapy with fenofibric acid. Discontinue fenofibric acid if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST > 3 times the upper limit of normal, or if accompanied by elevation of bilirubin). Do not restart fenofibric acid in these patients if there is no alternative explanation for the liver injury.

    5.3 Myopathy and Rhabdomyolysis

    Fibrates increase the risk of myositis or myopathy and have been associated with rhabdomyolysis. The risk for serious muscle toxicity appears to be increased in elderly patients and in patients with diabetes, renal failure, or hypothyroidism.

    Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevations of CPK levels. Patients should promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms, and fenofibric acid should be discontinued if markedly elevated CPK levels occur or myopathy or myositis is suspected or diagnosed.

    Data from observational studies suggest that the risk for rhabdomyolysis is increased when fibrates are co-administered with a statin.

    Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine [see Drug Interactions (7.4)].


    5.4 Serum Creatinine

    Reversible elevations in serum creatinine have been reported in patients receiving fenofibric acid as well as patients receiving fenofibrate. In the pooled analysis of three 12-week, double-blind, controlled studies of fenofibric acid, increases in creatinine to > 2 mg/dL occurred in 0.8% of patients treated with fenofibric acid without other lipid-altering drugs. Elevations in serum creatinine were generally stable over time with no evidence for continued increases in serum creatinine with long-term therapy and tended to return to baseline following discontinuation of treatment. The clinical significance of these observations is unknown. Monitoring renal function in patients with renal impairment taking fenofibric acid is suggested. Renal monitoring should be considered for patients at risk for renal insufficiency, such as the elderly and those with diabetes.

    5.5 Cholelithiasis

    Fenofibric acid, like fenofibrate, clofibrate, and gemfibrozil, may increase cholesterol excretion into the bile, potentially leading to cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated. Fenofibric acid therapy should be discontinued if gallstones are found.

    5.6 Coumarin Anticoagulants

    Caution should be exercised when fenofibric acid is given in conjunction with oral coumarin anticoagulants. Fenofibric acid may potentiate the anticoagulant effects of these agents resulting in prolongation of the prothrombin time/International Normalized Ratio (PT/INR). Frequent monitoring of PT/INR and dose adjustment of the oral anticoagulant are recommended until the PT /INR has stabilized in order to prevent bleeding complications [see Drug Interactions (7.1)].

    5.7 Pancreatitis

    Pancreatitis has been reported in patients taking drugs of the fibrate class, including fenofibric acid. This occurrence may represent a failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.

    5.8 Hematological Changes

    Mild to moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients following initiation of fenofibric acid and fenofibrate therapy. However, these levels stabilize during long-term administration. Thrombocytopenia and agranulocytosis have been reported in individuals treated with fenofibrates. Periodic monitoring of red and white blood cell counts are recommended during the first 12 months of fenofibric acid administration.

    5.9 Hypersensitivity Reactions

    Acute Hypersensitivity
    Anaphylaxis and angioedema have been reported postmarketing with fenofibrate. In some cases, reactions were life-threatening and required emergency treatment. If a patient develops signs or symptoms of an acute hypersensitivity reaction, advise them to seek immediate medical attention and discontinue fenofibrate. 
     
    Delayed Hypersensitivity
    Severe cutaneous adverse drug reactions (SCAR), including Stevens-Johnson syndrome, toxic epidermal necrolysis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported postmarketing, occurring days to weeks after initiation of fenofibrate. The cases of DRESS were associated with cutaneous reactions (such as rash or exfoliative dermatitis) and a combination of eosinophilia, fever, systemic organ involvement (renal, hepatic, or respiratory). Discontinue fenofibrate and treat patients appropriately if SCAR is suspected.

    5.10 Venothromboembolic Disease

    In the FIELD trial, pulmonary embolus (PE) and deep vein thrombosis (DVT) were observed at higher rates in the fenofibrate- than the placebo-treated group. Of 9,795 patients enrolled in FIELD, there were 4,900 in the placebo group and 4,895 in the fenofibrate group. For DVT, there were 48 events (1%) in the placebo group and 67 (1%) in the fenofibrate group (p = 0.074); and for PE, there were 32 (0.7%) events in the placebo group and 53 (1%) in the fenofibrate group (p = 0.022).
    In the Coronary Drug Project, a higher proportion of the clofibrate group experienced definite or suspected fatal or nonfatal PE or thrombophlebitis than the placebo group (5.2% vs. 3.3% at five years; p < 0.01).


    5.11 Paradoxical Decreases in HDL Cholesterol Levels

    There have been postmarketing and clinical trial reports of severe decreases in HDL cholesterol levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibrate therapy. The decrease in HDL-C is mirrored by a decrease in apolipoprotein A1. This decrease has been reported to occur within 2 weeks to years after initiation of fibrate therapy. The HDL-C levels remain depressed until fibrate therapy has been withdrawn; the response to withdrawal of fibrate therapy is rapid and sustained. The clinical significance of this decrease in HDL-C is unknown. It is recommended that HDL-C levels be checked within the first few months after initiation of fibrate therapy. If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline, and fibrate therapy should not be re-initiated.

  • 6 ADVERSE REACTIONS

    The following serious adverse reactions are described below and elsewhere in the labeling:
     Mortality and coronary heart disease morbidity [see Warnings and Precautions (5.1)]
     Hepatoxicity [see Warnings and Precautions (5.2)]
     Pancreatitis [see Warnings and Precautions (5.7)]
     Hypersensitivity reactions [see Warnings and Precautions (5.9)]
     Venothromboembolic disease [see Warnings and Precautions (5.10)]


    6.1 Clinical Trials Experience

    Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
    Fenofibric acid is the active metabolite of fenofibrate. Adverse events reported by 2% or more of patients treated with fenofibrate and greater than placebo during double-blind, placebocontrolled trials are listed in Table 1. Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.
    Table 1. Adverse Events Reported by 2% or More of Patients Treated with Fenofibrate and Greater than


    BODY SYSTEM
    Adverse Event
    		Fenofibrate*
    (N=439)
    		Placebo
    (N=365)
    BODY AS A WHOLE
    		 
    		 
    Abdominal Pain
    		4.6%
    		4.4%
    Back Pain
    		3.4%
    		2.5%
    Headache
    		3.2%
    		2.7%
    DIGESTIVE
    		 
    		 
    Nausea
    		2.3%
    		1.9%
    Constipation
    		2.1%
    		1.4%
    INVESTIGATIONS
    		 
    		 
    Abnormal Liver Tests
    		7.5%
    		1.4%
    Increased AST
    		3.4%
    		0.5%
    Increased ALT
    		3.0%
    		1.6%
    Increased Creatine
    Phosphokinase
    		3.0%
    		1.4%
    RESPIRATORY
    		 
    		 
    Respiratory Disorder
    		6.2%
    		5.5%
    Rhinitis
    		2.3%
    		1.1%
    * Dosage equivalent to 135 mg fenofibric acid

    Placebo During the Double-Blind, Placebo-Controlled Trials
    Urticaria was seen in 1.1% vs. 0%, and rash in 1.4% vs. 0.8% of fenofibrate and placebo patients respectively in controlled trials.

    Clinical trials with fenofibric acid did not include a placebo-control arm. However, the adverse event profile of fenofibric acid was generally consistent with that of fenofibrate. The following adverse events not listed above were reported in ≥ 3% of patients taking fenofibric acid alone:
    Gastrointestinal Disorders: Diarrhea, dyspepsia
    General Disorders and Administration Site Conditions: Pain
    Infections and Infestations: Nasopharyngitis, sinusitis, upper respiratory tract infection
    Musculoskeletal and Connective Tissue Disorders: Arthralgia, myalgia, pain in extremity
    Nervous System Disorders: Dizziness

    Increases in Liver Enzymes
    In a pooled analysis of three 12-week, double-blind, controlled studies of fenofibric acid, increases in ALT and AST > 3 times the upper limit of normal on two consecutive occasions occurred in 1.9% and 0.2%, respectively, of patients receiving fenofibric acid 135 mg daily and placebo, without other lipid-altering drugs. In a pooled analysis of 10 placebo-controlled trials, increases to > 3 times the upper limit of normal in ALT occurred in 5.3% of patients taking fenofibrate versus 1.1% of patients treated with placebo. In an 8-week study, the incidence of ALT or AST
    elevations ≥ 3 times the upper limit of normal was 13% in patients receiving dosages equivalent
    to 90 mg to 135 mg fenofibric acid daily and was 0% in those receiving dosages equivalent to 45 mg or less fenofibric acid daily or placebo.

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during postapproval use of fenofibrate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: rhabdomyolysis, pancreatitis, renal failure, muscle spasms, acute renal failure, hepatitis, cirrhosis, increased total bilirubin, anemia, asthenia, severely depressed HDL-cholesterol levels, and interstitial lung disease. Photosensitivity reactions to fenofibrate have occurred days to months after initiation; in some of these cases, patients reported a prior photosensitivity reaction to ketoprofen.

  • 7 DRUG INTERACTIONS

    7.1 Coumarin Anticoagulants

    Potentiation of coumarin-type anticoagulant effect has been observed with prolongation of the PT/INR.
    Caution should be exercised when oral coumarin anticoagulants are given in conjunction with fenofibric acid. The dosage of the anticoagulant should be reduced to maintain the PT/INR at the desired level to prevent bleeding complications. Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized [see Warnings and Precautions (5.6)].


    7.2 Bile Acid Binding Resins

    Since bile acid binding resins may bind other drugs given concurrently, patients should take fenofibric acid at least 1 hour before or 4 to 6 hours after a bile acid resin to avoid impeding its absorption.

    7.3 Immunosuppressants

    Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of drugs of the fibrate class including fenofibric acid, there is a risk that an interaction will lead to deterioration of renal function. The benefits and risks of using fenofibric acid with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed.

    7.4 Colchicine

    Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary
    Limited available data with fenofibrate use in pregnant women are insufficient to determine a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no evidence of embryo-fetal toxicity was observed with oral administration of fenofibrate in rats and rabbits during organogenesis at doses less than or equivalent to the maximum recommended clinical dose of 135 mg daily, based on body surface area (mg/m2). Adverse reproductive outcomes occurred at higher doses in the presence of maternal toxicity (see Data). Fenofibric acid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
    Data
    Animal Data
    In pregnant rats given oral dietary doses of 14, 127, and 361 mg/kg/day from gestation day 6-15 during the period of organogenesis, no adverse developmental findings were observed at 14 mg/kg/day (less than the clinical exposure at the maximum recommended human dose [MRHD] of 300 mg fenofibrate daily, equivalent to 135 mg fenofibric acid daily, based on body surface area comparisons). Increased fetal skeletal malformations were observed at maternally toxic doses (361 mg/kg/day, corresponding to 12 times the clinical exposure at the MRHD) that significantly suppressed maternal body weight gain.
    In pregnant rabbits given oral gavage doses of 15, 150, and 300 mg/kg/day from gestation day 6-18 during the period of organogenesis and allowed to deliver, no adverse developmental findings were observed at 15 mg/kg/day (a dose that approximates the clinical exposure at the MRHD, based on body surface area comparisons). Aborted litters were observed at maternally toxic doses (≥ 150 mg/kg/day, corresponding to ≥ 10 times the clinical exposure at the MRHD) that suppressed maternal body weight gain.

    In pregnant rats given oral dietary doses of 15, 75, and 300 mg/kg/day from gestation day 15 through lactation day 21 (weaning), no adverse developmental effects were observed at 15 mg/kg/day (less than the clinical exposure at the MRHD, based on body surface area comparisons), despite maternal toxicity (decreased weight gain). Post-implantation loss was observed at ≥ 75 mg/kg/day (≥ 2 times the clinical exposure at the MRHD) in the presence of maternal toxicity (decreased weight gain). Decreased pup survival was noted at 300 mg/kg/day (10 times the clinical exposure at the MRHD), which was associated with decreased maternal body weight gain/maternal neglect.

    8.2 Lactation

    Risk Summary
    There is no available information on the presence of fenofibrate in human milk, effects of the drug on the breastfed infant, or the effects on milk production. Fenofibrate is present in the milk of rats, and is therefore likely to be present in human milk. Because of the potential for serious adverse reactions in breastfed infants, such as disruption of infant lipid metabolism, women should not breastfeed during treatment with fenofibric acid and for 5 days after the final dose [see Contraindications (4)].


    8.4 Pediatric Use

    The safety and effectiveness of fenofibric acid in pediatric patients have not been established.

    8.5 Geriatric Use

    Fenofibric acid is substantially excreted by the kidney as fenofibric acid and fenofibric acid glucuronide, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Fenofibric acid exposure is not influenced by age. Since elderly patients have a higher incidence of renal impairment, dose selection for the elderly should be made on the basis of renal function [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]. Elderly patients with normal renal function should require no dose modifications. Consider monitoring renal function in elderly patients taking fenofibric acid.

    8.6 Renal Impairment

    The use of fenofibric acid should be avoided in patients who have severe renal impairment [see Contraindications (4)]. Dose reduction is required in patients with mild to moderate renal impairment [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. Monitoring renal function in patients with renal impairment is recommended.

    8.7 Hepatic Impairment

    The use of fenofibric acid delayed-release capsules has not been evaluated in subjects with hepatic impairment [see Contraindications (4) and Clinical Pharmacology (12.3)].

  • 10 OVERDOSAGE

    There is no specific treatment for overdose with fenofibric acid. General supportive care of the patient is indicated, including monitoring of vital signs and observation of clinical status, should an overdose occur. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. Because fenofibric acid is highly bound to plasma proteins, hemodialysis should not be considered.

  • 11 DESCRIPTION

    Fenofibric acid is a lipid regulating agent available as delayed release capsules for oral administration. Each delayed release capsule contains choline fenofibrate, equivalent to 45 mg or 135 mg of fenofibric acid. The chemical name for choline fenofibrate is ethanaminium, 2- hydroxy-N,N,N-trimethyl, 2-{4-(4-chlorobenzoyl)phenoxy] -2-methylpropanoate (1:1) with the following structural formula:


    111

    The molecular formula is C22H28ClNO5 and the molecular weight is 421.91. Choline fenofibrate is freely soluble in water. The melting point is approximately 210°C. Choline fenofibrate is a white to yellow powder, which is stable under ordinary conditions.
    Each delayed-release capsule contains enteric coated mini-tablets comprised of choline fenofibrate and the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methyl cellulose, methacrylic acid copolymer, microcrystalline cellulose, povidone, sodium stearyl fumarate, talc and triethyl citrate.
    The capsule shell of the 45 mg capsule contains the following inactive ingredients: gelatin, iron oxide black, iron oxide red, iron oxide yellow, sodium lauryl sulfate and titanium dioxide.
    The capsule shell of the 135 mg capsule contains the following inactive ingredients: FD&C Blue #2, iron oxide yellow, sodium lauryl sulfate and gelatin, titanium dioxide.


  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The active moiety of fenofibric acid delayed-release capsules is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been extensively studied through oral administration of fenofibrate.
    The lipid-modifying effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPARα). Through this mechanism, fenofibric acid increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of Apo CIII (an inhibitor of lipoprotein lipase activity).
    Activation of PPARα also induces an increase in the synthesis of HDL-C and Apo AI and AII.


    12.3 Pharmacokinetics

    Fenofibric acid delayed-release capsules contain fenofibric acid, which is the only circulating pharmacologically active moiety in plasma after oral administration of fenofibric acid delayed-release capsules. Fenofibric acid is also the circulating pharmacologically active moiety in plasma after oral administration of fenofibrate, the ester of fenofibric acid.
    Plasma concentrations of fenofibric acid after administration of one 135 mg fenofibric acid delayed-release capsules are equivalent to those after one 200 mg capsule of micronized fenofibrate administered under fed conditions.

    Absorption
    Fenofibric acid is well absorbed throughout the gastrointestinal tract. The absolute bioavailability of fenofibric acid is approximately 81%.

    Peak plasma levels of fenofibric acid occur within 4 to 5 hours after a single dose administration of fenofibric acid delayed-release capsules under fasting conditions.

    Fenofibric acid exposure in plasma, as measured by Cmax and AUC, is not significantly different when a single 135 mg dose of fenofibric acid is administered under fasting or nonfasting conditions.

    Distribution
    Upon multiple dosing of fenofibric acid, fenofibric acid levels reach steady state within 8 days. Plasma concentrations of fenofibric acid at steady state are approximately slightly more than double those following a single dose. Serum protein binding is approximately 99% in normal and dyslipidemic subjects.

    Metabolism
    Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. A small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite which is, in turn, conjugated with glucuronic acid and excreted in urine.

    In vivo metabolism data after fenofibrate administration indicate that fenofibric acid does not undergo oxidative metabolism (e.g., cytochrome P450) to a significant extent.

    Elimination
    After absorption, fenofibric acid is primarily excreted in the urine in the form of fenofibric acid and fenofibric acid glucuronide.
    Fenofibric acid is eliminated with a half-life of approximately 20 hours, allowing once daily administration of fenofibric acid.

    Specific Populations
    Geriatrics
    In five elderly volunteers 77 to 87 years of age, the oral clearance of fenofibric acid following a single oral dose of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults. This indicates that an equivalent dose of fenofibric acid can be used in elderly subjects with normal renal function, without increasing accumulation of the drug or metabolites [see Use in Specific Populations (8.5)].

    Pediatrics
    The pharmacokinetics of fenofibric acid has not been studied in pediatric populations.

    Gender
    No pharmacokinetic difference between males and females has been observed for fenofibric acid.

    Race
    The influence of race on the pharmacokinetics of fenofibric acid has not been studied; however, fenofibric acid is not metabolized by enzymes known for exhibiting inter-ethnic variability.

    Renal Impairment
    The pharmacokinetics of fenofibric acid was examined in patients with mild, moderate, and severe renal impairment. Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m2) showed a 2.7-fold increase in exposure for fenofibric acid and increased accumulation of fenofibric acid during chronic dosing compared to that of healthy subjects. Patients with mild to moderate renal impairment (eGFR 30-59 mL/min/1.73m2) had similar exposure but an increase in the half-life for fenofibric acid compared to that of healthy subjects. Based on these findings, the use of fenofibric acid should be avoided in patients who have severe renal impairment and dose reduction is required in patients having mild to moderate renal impairment [see Dosage and Administration (2.4)].

    Hepatic Impairment
    No pharmacokinetic studies have been conducted in patients with hepatic impairment.

    Drug-drug Interactions
    In vitro studies using human liver microsomes indicate that fenofibric acid is not an inhibitor of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. It is a weak inhibitor of CYP2C8, CYP2C19, and CYP2A6, and mild-to-moderate inhibitor of CYP2C9 at therapeutic concentrations.

    Comparison of atorvastatin exposures when atorvastatin (80 mg once daily for 10 days) is given in combination with fenofibric acid (fenofibric acid 135 mg once daily for 10 days) and ezetimibe (10 mg once daily for 10 days) versus when atorvastatin is given in combination with ezetimibe only (ezetimibe 10 mg once daily and atorvastatin, 80 mg once daily for 10 days): The Cmax decreased by 1% for atorvastatin and ortho-hydroxy-atorvastatin and increased by 2% for parahydroxy-atorvastatin. The AUC decreased 6% and 9% for atorvastatin and orthohydroxy-atorvastatin, respectively, and did not change for para-hydroxy-atorvastatin.

    Comparison of ezetimibe exposures when ezetimibe (10 mg once daily for 10 days) is given in combination with fenofibric acid (fenofibric acid 135 mg once daily for 10 days) and atorvastatin (80 mg once daily for 10 days) versus when ezetimibe is given in combination with atorvastatin only (ezetimibe 10 mg once daily and atorvastatin, 80 mg once daily for 10 days): The Cmax increased by 26% and 7% for total and free ezetimibe, respectively. The AUC increased by 27% and 12% for total and free ezetimibe, respectively.

    Table 2 describes the effects of co-administered drugs on fenofibric acid systemic exposure.
    Table 3 describes the effects of co-administered fenofibric acid on other drugs.


    Table 2. Effects of Co-Administered Drugs on Fenofibric Acid Systemic Exposure from Fenofibric Acid Delayed-Release Capsules or Fenofibrate Administration


    Co-Administered Drug
    		Dosage Regimen of Co-Administered Drug
    		Dosage Regimen of  Fenofibric Acid delayed-release capsulesor Fenofibrate
    		Changes in Fenofibric Acid Exposure

    		AUC
    		Cmax
    Lipid-lowering agents
    Rosuvastatin
    		40 mg once daily for 10 days
    		Fenofibric acid delayed-release capsules 135 mgonce daily for 10 days
    		↓2%
    		↓2%
    Atorvastatin
    		20 mg once daily for 10 days
    		Fenofibrate 160 mg1  once daily for 10 days
    		↓2%
    		↓4%
    Atorvastatin + ezetimibe
    		Atorvastatin, 80 mg once daily and ezetimibe, 10 mg once daily for 10 days
    		Fenofibric acid delayed-release capsules 135 mg once daily for 10 days
    		↑5%
    		↑5%
    Pravastatin
    		40 mg as a single dose
    		Fenofibrate 3 x 67mg 2  as a single dose
    		↓1%
    		↓2%
    Fluvastatin
    		40 mg as a single dose
    		Fenofibrate 160 mg1 as a single dose
    		↓2%
    		↓10%
    Simvastatin
    		80 mg once daily for 7 days
    		Fenofibrate 160 mg1  once daily for 7 days
    		↓5%
    		↓11%
    Anti-diabetic agents
    Glimepiride
    		1 mg as a single dose
    		Fenofibrate 145 mg1 once daily for 10 days
    		↑1%
    		↓1%
    Metformin
    		850 mg 3 times daily for 10 days
    		Fenofibrate 54 mg1  3 times daily for 10 days
    		↓9%
    		↓6%
    Rosiglitazone
    		8 mg once daily for 5 days
    		Fenofibrate 145 mg1 once daily for 14 days
    		↑10%
    		↑3%
    Gastrointestinal agents
    Omeprazole
    		40 mg once daily for 5 days
    		Fenofibric acid 135 mg as a single dose fasting
    		↑6%
    		↑17%
    Omeprazole
    		40 mg once daily for 5 days
    		Fenofibric acid 135 mg as a single dose with food
    		↑4%
    		↓2%
    1 TriCor (fenofibrate) oral tablet
    2 TriCor (fenofibrate) oral micronized capsule

     

    Table 3. Effects of Fenofibric Acid or Fenofibrate Co-Administration on Systemic Exposure of Other Drugs


    Dosage Regimen of Fenofibric Acid Delayed-Release Capsules of Fenofibrate
    		Dosage Regimen of Co-Administered Drug
    		Change in Co-Administered Drug Exposure
     
    		 
    		Analyte
    		AUC
    		Cmax
    Lipid-lowering agents
    Fenofibric acid delayed-release capsules 135 mg once daily for 10 days
    		Rosuvastatin, 40 mg once daily for 10 days
    		Rosuvastatin
    		↑6%
    		↑20%
    Fenofibrate 160 mg1 once daily for 10 days
    		Atorvastatin, 20 mg once daily for 10 days
    		Atorvastatin
    		↓17%
    		0%
    Fenofibrate 3 x 67 mg2 as a single dose
    		Pravastatin, 40 mg as a single dose
    		Pravastatin
    		↑13%
    		↑13%
     
    		 
    		3α-Hydroxyl-iso-pravastatin
    		↑26%
    		↑29%
    Fenofibrate 160 mg1 as a single dose
    		Fluvastatin, 40 mg as a single dose
    		(+)-3R, 5S-Fluvastatin
    		↑15%
    		↑16%
    Fenofibrate 160 mg1 once daily for 7 days
    		Simvastatin, 80 mg once daily for 7 days
    		Simvastatin acid
    		↓36%
    		↓11%
     
    		 
    		Simvastatin
    		↓11%
    		↓17%
     
    		 
    		Active HMG-CoA Inhibitors
    		↓12%
    		↓1%
     
    		 
    		Total HMG-CoA Inhibitors
    		↓8%
    		↓10%
    Anti-diabetic agents
    Fenofibrate 145 mg1 once daily for 10 days
    		Glimepiride, 1 mg as a single dose
    		Glimepiride
    		↑35%
    		↑18%
    Fenofibrate 54 mg1 3 times daily for  10 days
    		Metformin, 850 mg 3 times daily for 10 days
    		Metformin
    		↑3%
    		↑6%
    Fenofibrate 145 mg1 once daily for 14 days
    		Rosiglitazone, 8 mg once daily for 5 days
    		Rosiglitazone
    		↑6%
    		↓1%
    1 TriCor (fenofibrate) oral tablet
    2 TriCor (fenofibrate) oral micronized capsule

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis & Mutagenesis & Impairment Of Fertility

    Fenofibric acid
    No carcinogenicity and fertility studies have been conducted with choline fenofibrate or fenofibric acid. However, because fenofibrate is rapidly converted to its active metabolite, fenofibric acid, either during or immediately following absorption both in animals and humans, studies conducted with fenofibrate are relevant for the assessment of the toxicity profile of fenofibric acid. A similar toxicity spectrum is expected after treatment with either fenofibric acid or fenofibrate.

    Fenofibrate
    Two dietary carcinogenicity studies have been conducted in rats with fenofibrate. In the first 24-month study, Wistar rats were dosed with fenofibrate at 10, 45, and 200 mg/kg/day, approximately 0.3, 1, and 6 times the maximum recommended human dose (MRHD) of 300 mg fenofibrate daily, equivalent to 135 mg fenofibric acid daily, based on body surface area comparisons. At a dose of 200 mg/kg/day (at 6 times the MRHD), the incidence of liver carcinomas was significantly increased in both sexes. A statistically significant increase in pancreatic carcinomas was observed in males at 1 and 6 times the MRHD; an increase in pancreatic adenomas and benign testicular interstitial cell tumors was observed at 6 times the MRHD in males. In a second 24-month rat carcinogenicity study in a different strain of rats (Sprague-Dawley), doses of 10 and 60 mg/kg/day (0.3 and 2 times the MRHD) produced significant increases in the incidence of pancreatic acinar adenomas in both sexes and increases in testicular interstitial cell tumors in males at 2 times the MRHD.

    A 117-week carcinogenicity study was conducted in rats comparing three drugs: fenofibrate 10 and 60 mg/kg/day (0.3 and 2 times the MRHD, based on body surface area comparisons), clofibrate (400 mg/kg/day; 2 times the human dose), and gemfibrozil (250 mg/kg/day; 2 times the human dose, based on mg/m2surface area). Fenofibrate increased pancreatic acinar adenomas in both sexes. Clofibrate increased hepatocellular carcinoma and pancreatic acinar adenomas in males and hepatic neoplastic nodules in females. Gemfibrozil increased hepatic neoplastic nodules in males and females, while all three drugs increased testicular interstitial cell tumors in males.

    In a 21-month study in CF-1 mice, fenofibrate 10, 45, and 200 mg/kg/day (approximately 0.2, 1, and 3 times the MRHD, based on body surface area comparisons) significantly increased the liver carcinomas in both sexes at 3 times the MRHD. In a second 18-month study at 10, 60, and 200 mg/kg/day, fenofibrate significantly increased the liver carcinomas in male mice and liver adenomas in female mice at 3 times the MRHD.

    Electron microscopy studies have demonstrated peroxisomal proliferation following fenofibrate administration to the rat. An adequate study to test for peroxisome proliferation in humans has not been done, but changes in peroxisome morphology and numbers have been observed in humans after treatment with other members of the fibrate class when liver biopsies were compared before and after treatment in the same individual.

    Fenofibrate has been demonstrated to be devoid of mutagenic potential in the following tests: Ames, mouse lymphoma, chromosomal aberration and unscheduled DNA synthesis in primary rat hepatocytes.

    In fertility studies rats were given oral dietary doses of fenofibrate, males received 61 days prior to mating and females 15 days prior to mating through weaning which resulted in no adverse effect on fertility at doses up to 300 mg/kg/day (10 times the MRHD, based on body surface area comparisons).

  • 14 CLINICAL STUDIES

    14.1 Severe Hypertriglyceridemia

    The effects of fenofibrate on serum triglycerides were studied in two randomized, double-blind, placebo-controlled clinical trials of 147 hypertriglyceridemic patients. Patients were treated for eight weeks under protocols that differed only in that one entered patients with baseline TG levels of 500 to 1500 mg/dL, and the other TG levels of 350 to 500 mg/dL. In patients with hypertriglyceridemia and normal cholesterolemia with or without hyperchylomicronemia, treatment with fenofibrate at dosages equivalent to 135 mg once daily of fenofibric acid delayed-release capsules decreased primarily VLDL-TG and VLDL-C. Treatment of patients with elevated TG often results in an increase of LDL-C (Table 4).
    Table 4. Effects of Fenofibrate in Patients With Severe Hypertriglyceridemia


    Study 1
    		Placebo
    		Fenofibrate
    Baseline TG levels 350 to 499 mg/dL
    		N
    		Baseline Mean (mg/dL)
    		Endpoint Mean (mg/dL)
    		Mean % Change
    		N
    		Baseline Mean (mg/dL)
    		Endpoint Mean (mg/dL)
    		Mean % Change
    Triglycerides
    		28  
    		449
    		450
    		-0.5
    		27
    		432
    		223
    		-46.2*
    VLDL Triglycerides
    		19
    		367
    		350
    		2.7
    		19
    		350
    		178
    		-44.1*
    Total Cholesterol
    		28
    		255
    		261
    		2.8
    		27
    		252
    		227
    		-9.1*
    HDL Cholesterol
    		28
    		35
    		36
    		4
    		27
    		34
    		40
    		19.6*
    LDL Cholesterol
    		28
    		120
    		129
    		12
    		27
    		128
    		137
    		14.5
    VLDL Cholesterol
    		27
    		99
    		99
    		5.8
    		27
    		92
    		46
    		-44.7*
    Study 2
    		Placebo
    		Fenofibrate
    Baseline TG levels 500 to 1500 mg/dL
    		N
    		Baseline Mean (mg/dL)
    		Endpoint Mean (mg/dL)
    		Mean % Change
    		N
    		Baseline Mean (mg/dL)
    		Endpoint Mean (mg/dL)
    		Mean % Change
    Triglycerides
    		44
    		710
    		750
    		7.2
    		48
    		726
    		308
    		-54.5*
    VLDL Triglycerides
    		29
    		537
    		571
    		18.7
    		33
    		543
    		205
    		-50.6*
    Total Cholesterol
    		44
    		272
    		271
    		0.4
    		48
    		261
    		223
    		-13.8*
    HDL Cholesterol
    		44
    		27
    		28
    		5.0
    		48
    		30
    		36
    		22.9*
    LDL Cholesterol
    		42
    		100
    		90
    		-4.2
    		45
    		103
    		131
    		45.0*
    VLDL Cholesterol
    		42
    		137
    		142
    		11.0
    		45
    		126
    		54
    		-49.4*
    * = p < 0.05 vs. Placebo

    14.2 Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia

    The effects of fenofibrate at a dose equivalent to fenofibric acid 135 mg once daily were assessed from four randomized, placebo-controlled, double-blind, parallel-group studies including patients with the following mean baseline lipid values: Total-C 306.9 mg/dL; LDL-C 213.8 mg/dL; HDL-C 52.3 mg/dL; and triglycerides 191.0 mg/dL. Fenofibrate therapy lowered LDL-C, Total-C, and the LDL-C/HDL-C ratio. Fenofibrate therapy also lowered triglycerides and raised HDL-C (Table 5).
    Table 5. Mean Percent Change in Lipid Parameters at End of Treatment†


    Treatment Group
    		Total-C (mg/dL)
    		LDL-C (mg/dL)
    		HDL-C(mg/dL)
    		TG (mg/dL)
    Pooled Cohort
    		 
    		 
    		 
    		 
    Mean baseline lipid values (n = 646)
    		306.9
    		213.8
    		52.3
    		191.0
    All Fenofibrate (n = 361)
    		-18.7%*
    		-20.6%*
    		+11.0%*
    		-28.9%*
    Placebo (n = 285)
    		-0.4%
    		-2.2%
    		+0.7%
    		+7.7%
    Baseline LDL-C > 160 mg/dL and TG < 150 mg/dL
    		 
    		 
    		 
    		 
    Mean baseline lipid values (n =334)
    		307.7
    		227.7
    		58.1
    		101.7
    All Fenofibrate (n = 193)
    		-22.4%*
    		-31.4%*
    		+9.8%*
    		-23.5%*
    Placebo (n = 141)
    		+0.2%
    		-2.2%
    		+2.6%
    		+11.7%
    Baseline LDL-C > 160 mg/dL and TG≥ 150 mg/dL
    		 
    		 
    		 
    		 
    Mean baseline lipid values (n = 242)
    		312.8
    		219.8
    		46.7
    		231.9
    All Fenofibrate (n= 126)
    		-16.8%*
    		-20.1%*
    		+14.6%*
    		-35.9%*
    Placebo (n= 116)
    		-3.0%
    		-6.6%
    		+2.3%
    		+0.9%
    †Duration of study treatment was 3 to 6 months
    * p = < 0.05 vs. Placebo

    In a subset of the subjects, measurements of Apo B were conducted. Fenofibrate treatment significantly reduced Apo B from baseline to endpoint as compared with placebo (-25.1 % vs. 2.4%, p < 0.0001, n = 213 and 143, respectively).

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Fenofibric acid delayed-release capsules, 45 mg:
     A reddish brown cap/yellow body size “3” capsule containing white to off white delayed release, biconvex mini tablets, with ‘C 66’ on body imprinted with black ink.
    NDC: 33342-294-10 Bottles of 90
    NDC: 33342-294-12 Blister of 100’s (10 x 10's)

    Fenofibric acid delayed-release capsules, 135 mg:
     A blue cap/yellow body size “0” capsule containing white to off white delayed release, biconvex mini tablets, with ‘C 67’ on body imprinted with black ink.
    NDC: 33342-295-10 Bottle of 90
    NDC: 33342-295-56 Blister of 140’s (10 x 14's)


    Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture.

  • 17 PATIENT COUNSELING INFORMATION

    Patient Counseling
    Patients should be advised:
     of the potential benefits and risks of fenofibric acid delayed-release capsules.
     not to use fenofibric acid delayed-release capsules if there is a known hypersensitivity to fenofibrate or fenofibric acid.
     of medications that should not be taken in combination with fenofibric acid delayed-release capsules.
     that if they are taking coumarin anticoagulants, fenofibric acid delayed-release capsules may increase their anti-coagulant effect, and increased monitoring may be necessary.
     to continue to follow an appropriate lipid-modifying diet while taking fenofibric acid delayed-release capsules.
     to take fenofibric acid delayed-release capsules once daily, without regard to food, at the prescribed dose, swallowing each capsule whole.
     to return to their physician’s office for routine monitoring.
     to inform their physician of all medications, supplements, and herbal preparations they are taking and any change to their medical condition. Patients should also be advised to inform their physicians prescribing a new medication that they are taking fenofibric acid delayed-release capsules.
     to inform their physician of symptoms of liver injury (e.g., jaundice, abdominal pain, nausea, malaise, dark urine, abnormal stool, pruritus); any muscle pain, tenderness, or weakness; or any other new symptoms.
     not to breastfeed during treatment with fenofibric acid delayed-release capsules and for 5 days after the final dose.

     
    Manufactured for:
    Macleods Pharma USA, Inc.
    Princeton, NJ 08540


    Manufactured by:
    Macleods Pharmaceuticals Limited
    Baddi, INDIA

    Revised: February,2024

    All trademarks are a property of their respective owner

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Fenofibric Acid Delayed-Release Capsules, 45 mg
    90's Capsule Container
    NDC No.: 33342-294-10
     186
    Fenofibric Acid Delayed-Release Capsules, 45 mg
    100’s (10 x 10's) Carton
    NDC No: 33342-294-12
    163
    Fenofibric Acid Delayed-Release Capsules, 135 mg
    90's Capsule Container
    NDC No.: 33342-295-10

    164
    Fenofibric Acid Delayed-Release Capsules, 45 mg
    140’s (14 x 10's) Carton
    NDC No: 33342-295-56

    174

  • INGREDIENTS AND APPEARANCE
    FENOFIBRIC ACID 
    fenofibric acid capsule, delayed release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 33342-294
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CHOLINE FENOFIBRATE (UNII: 4BMH7IZT98) (FENOFIBRIC ACID - UNII:BGF9MN2HU1) FENOFIBRIC ACID45 mg
    Inactive Ingredients
    Ingredient NameStrength
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    HYPROMELLOSE 2208 (4 MPA.S) (UNII: 58779NIC8P)  
    POVIDONE K30 (UNII: U725QWY32X)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)  
    GELATIN (UNII: 2G86QN327L)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    TALC (UNII: 7SEV7J4R1U)  
    TRIETHYL CITRATE (UNII: 8Z96QXD6UM)  
    METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A (UNII: NX76LV5T8J)  
    Product Characteristics
    ColorRED (reddish brown cap) , YELLOW (yellow body) Scoreno score
    ShapeCAPSULE (Capsule) Size16mm
    FlavorImprint Code C66
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 33342-294-1090 in 1 BOTTLE; Type 0: Not a Combination Product02/26/2024
    2NDC: 33342-294-1210 in 1 CARTON02/26/2024
    210 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20779602/26/2024
    FENOFIBRIC ACID 
    fenofibric acid capsule, delayed release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 33342-295
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CHOLINE FENOFIBRATE (UNII: 4BMH7IZT98) (FENOFIBRIC ACID - UNII:BGF9MN2HU1) FENOFIBRIC ACID135 mg
    Inactive Ingredients
    Ingredient NameStrength
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    HYPROMELLOSE 2208 (4 MPA.S) (UNII: 58779NIC8P)  
    POVIDONE K30 (UNII: U725QWY32X)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)  
    GELATIN (UNII: 2G86QN327L)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FD&C BLUE NO. 2 (UNII: L06K8R7DQK)  
    TALC (UNII: 7SEV7J4R1U)  
    TRIETHYL CITRATE (UNII: 8Z96QXD6UM)  
    METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A (UNII: NX76LV5T8J)  
    Product Characteristics
    ColorYELLOW (yellow body) , BLUE (blue cap) Scoreno score
    ShapeCAPSULE (Capsule) Size22mm
    FlavorImprint Code C67
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 33342-295-1090 in 1 BOTTLE; Type 0: Not a Combination Product02/26/2024
    2NDC: 33342-295-5610 in 1 CARTON02/26/2024
    214 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20779602/26/2024
    Labeler - Macleods Pharmaceuticals Limited (862128535)
    Establishment
    NameAddressID/FEIBusiness Operations
    Macleods Pharmaceuticals Limited676369519ANALYSIS(33342-294, 33342-295) , LABEL(33342-294, 33342-295) , MANUFACTURE(33342-294, 33342-295) , PACK(33342-294, 33342-295)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.